Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding.

IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pharmaceutical Statistics Pub Date : 2024-12-04 DOI:10.1002/pst.2457
Douglas Faries, Chenyin Gao, Xiang Zhang, Chad Hazlett, James Stamey, Shu Yang, Peng Ding, Mingyang Shan, Kristin Sheffield, Nancy Dreyer
{"title":"Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding.","authors":"Douglas Faries, Chenyin Gao, Xiang Zhang, Chad Hazlett, James Stamey, Shu Yang, Peng Ding, Mingyang Shan, Kristin Sheffield, Nancy Dreyer","doi":"10.1002/pst.2457","DOIUrl":null,"url":null,"abstract":"<p><p>The assumption of \"no unmeasured confounders\" is a critical but unverifiable assumption required for causal inference yet quantitative sensitivity analyses to assess robustness of real-world evidence remains under-utilized. The lack of use is likely in part due to complexity of implementation and often specific and restrictive data requirements for application of each method. With the advent of methods that are broadly applicable in that they do not require identification of a specific unmeasured confounder-along with publicly available code for implementation-roadblocks toward broader use of sensitivity analyses are decreasing. To spur greater application, here we offer a good practice guidance to address the potential for unmeasured confounding at both the design and analysis stages, including framing questions and an analytic toolbox for researchers. The questions at the design stage guide the researcher through steps evaluating the potential robustness of the design while encouraging gathering of additional data to reduce uncertainty due to potential confounding. At the analysis stage, the questions guide quantifying the robustness of the observed result and providing researchers with a clearer indication of the strength of their conclusions. We demonstrate the application of this guidance using simulated data based on an observational fibromyalgia study, applying multiple methods from our analytic toolbox for illustration purposes.</p>","PeriodicalId":19934,"journal":{"name":"Pharmaceutical Statistics","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pst.2457","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The assumption of "no unmeasured confounders" is a critical but unverifiable assumption required for causal inference yet quantitative sensitivity analyses to assess robustness of real-world evidence remains under-utilized. The lack of use is likely in part due to complexity of implementation and often specific and restrictive data requirements for application of each method. With the advent of methods that are broadly applicable in that they do not require identification of a specific unmeasured confounder-along with publicly available code for implementation-roadblocks toward broader use of sensitivity analyses are decreasing. To spur greater application, here we offer a good practice guidance to address the potential for unmeasured confounding at both the design and analysis stages, including framing questions and an analytic toolbox for researchers. The questions at the design stage guide the researcher through steps evaluating the potential robustness of the design while encouraging gathering of additional data to reduce uncertainty due to potential confounding. At the analysis stage, the questions guide quantifying the robustness of the observed result and providing researchers with a clearer indication of the strength of their conclusions. We demonstrate the application of this guidance using simulated data based on an observational fibromyalgia study, applying multiple methods from our analytic toolbox for illustration purposes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
真实效果还是偏见?通过对未测量混杂的定量敏感性分析评估比较观察性研究证据稳健性的良好实践。
“没有未测量的混杂因素”的假设是因果推理所需的一个关键但无法验证的假设,但用于评估真实世界证据稳健性的定量敏感性分析仍未得到充分利用。缺乏使用的部分原因可能是实现的复杂性,以及每种方法的应用通常需要特定和限制性的数据。随着广泛适用的方法的出现,它们不需要识别特定的未测量的混杂因素,以及公开可用的实现代码,更广泛使用敏感性分析的障碍正在减少。为了促进更广泛的应用,我们在这里提供了一个很好的实践指导,以解决在设计和分析阶段可能出现的不可测量的混淆,包括框架问题和研究人员的分析工具箱。设计阶段的问题指导研究人员通过评估设计的潜在稳健性的步骤,同时鼓励收集额外的数据,以减少由于潜在的混淆造成的不确定性。在分析阶段,这些问题指导量化观察结果的稳健性,并为研究人员提供更清晰的结论强度指示。我们使用基于观察性纤维肌痛研究的模拟数据来演示该指南的应用,应用我们分析工具箱中的多种方法来说明目的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmaceutical Statistics
Pharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.70
自引率
6.70%
发文量
90
审稿时长
6-12 weeks
期刊介绍: Pharmaceutical Statistics is an industry-led initiative, tackling real problems in statistical applications. The Journal publishes papers that share experiences in the practical application of statistics within the pharmaceutical industry. It covers all aspects of pharmaceutical statistical applications from discovery, through pre-clinical development, clinical development, post-marketing surveillance, consumer health, production, epidemiology, and health economics. The Journal is both international and multidisciplinary. It includes high quality practical papers, case studies and review papers.
期刊最新文献
A Commensurate Prior Model With Random Effects for Survival and Competing Risk Outcomes to Accommodate Historical Controls. Bayesian Sample Size Calculation in Small n, Sequential Multiple Assignment Randomized Trials (snSMART). Taylor Series Approximation for Accurate Generalized Confidence Intervals of Ratios of Log-Normal Standard Deviations for Meta-Analysis Using Means and Standard Deviations in Time Scale. A Bayesian Hybrid Design With Borrowing From Historical Study. WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1